Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Capreomycin is an aminoglycoside antibiotic used as a second-line drug in the treatment of tuberculosis when there is resistance to other drugs. Intramuscular or intravenous administration.
At the date of the last update we found no published data on its excretion in breast milk.
Its high molecular weight makes its excretion in breast milk unlikely.
Its practically null oral bioavailability (oral absorption less than 1%) prevents passage into the plasma of the infant from ingested breast milk, except in premature infants and the immediate neonatal period in which there may be greater intestinal permeability.
No adverse effects have been reported in infants breastfed by mothers treated with capreomycin that can be directly attributed to this drug. (Drobac 2005)